Prognostic significance(impact) of CD10protein expression in breast carcinoma
DOI:
https://doi.org/10.5457/ams.v45i1-2.430Keywords:
breast cancer recurrence, therapy resistant breast cancer, CD10 oncoprotein.Abstract
Introduction: Although the breast carcinoma is more rare in age under thirthy years than older one, tendency of aggresive occurrance of disease in younger patients results with lower rate of survival. Even though the breast is considered as the most investigated tissue, predicting the course of disease and prognosis of outcome are uncertain.
The objectiv of conducted research was to determine CD10 oncoprotein expression in primary and recurrent breast carcinoma, and to investigate the dependence of C10 oncoprotein expreion in primary and recurrent breast carcinomm on the histologic and nuclear grade, expression of estrogen, progesteron and Her2/neu receptors, and to correlate the CD10 oncoprotein expression with occurring of breast carcinoma recurrence.
Patient and Methods: The study analyzed 64 patients with primary diagnosed invasive ductal (NST) breast carcinoma, stadium T1N0 and T2N0, in period from 2004 to 2008. The patients had at least five years of survival. The patients were divided into two groups, examine with diseas recurrence, and control without it.
Results: It has been found that age, histologic grade and absens of expression of estrogen and progesteron receptors are not in correlation with occurance of disease recurrence, but the nuclear grade and positiv expression of Her2/neu receptors are highly correlated. CD10 showed high statisticlly significant correlation with breast carcinoma recurrence.
Conclusion: Nuclear grade and positiv expression of Her2/neu receptors are highly correlating parameters with breast carcinoma recurrence as well as CD10 protein exprsion. CD10 is predictor of clinical course and outcome of breast carcinoma independently on the other parameters and can be conidered as the target of specific therapy.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
